Residency · Residency · Dermatology

Basal Cell Carcinoma: Subtypes and Management

Epidemiology

Basal cell carcinoma is the most common human malignancy worldwide, with approximately 3 to 4 million cases diagnosed per year in the United States alone. The lifetime risk for Caucasians in high-UV regions is approximately 30 percent. Males are affected more than females at a ratio of roughly 1.5 to 2:1, and the median age at diagnosis is approximately 65 years, though incidence is increasing in younger adults, especially women, likely related to indoor tanning. Despite its frequency, metastasis is extremely rare (less than 0.05 percent), and mortality is low. However, BCC causes significant morbidity through local tissue destruction if left untreated.

Pathogenesis

Hedgehog (Hh) Signaling Pathway

BCC is fundamentally driven by aberrant activation of the Hedgehog pathway. In the normal state, PTCH1 (Patched) inhibits SMO (Smoothened). When ligand binds to PTCH1, SMO inhibition is released, activating GLI transcription factors. In BCC, loss-of-function mutations in PTCH1 (the most common alteration, occurring in approximately 70 percent of cases) or gain-of-function mutations in SMO (10 to 20 percent) lead to constitutive pathway activation. The downstream GLI1 and GLI2 transcription factors drive proliferation, survival, and stem cell maintenance. Gorlin syndrome (nevoid BCC syndrome) results from germline PTCH1 mutations inherited in an autosomal dominant pattern. Affected individuals develop multiple BCCs from a young age and may also have odontogenic keratocysts, skeletal anomalies, calcification of the falx cerebri, and an increased risk of medulloblastoma.

UV Radiation

UVB-induced signature mutations (C-to-T transitions) in tumor suppressor genes are central to BCC development. p53 mutations are present in approximately 50 percent of BCCs but are considered a secondary event. Unlike melanoma, where intermittent intense UV exposure is the primary driver, cumulative UV exposure is the predominant risk factor for BCC.

Other Risk Factors

Additional risk factors include ionizing radiation exposure (including prior radiotherapy), chronic arsenic exposure, immunosuppression, Fitzpatrick skin types I and II, and a history of prior BCCs, which confers a 36 to 50 percent risk of developing a subsequent BCC within 5 years. Notably, in immunosuppressed transplant recipients, the typical BCC-to-SCC ratio reverses, with SCCs predominating.

Clinical Subtypes

Nodular BCC (60-80%)

Nodular BCC is the most common subtype, presenting as a pearly, translucent papule or nodule with telangiectasias and a characteristic rolled border. Advanced lesions develop central ulceration, earning the term "rodent ulcer." It occurs most commonly on the head and neck, particularly the nose. Dermoscopy reveals arborizing vessels, blue-grey ovoid nests, ulceration, and shiny white structures.

Superficial BCC (10-30%)

Superficial BCC presents as an erythematous, slightly scaly patch or thin plaque with a thread-like pearly border. It is most common on the trunk and extremities and may be multifocal or quite extensive. Dermoscopy shows short fine telangiectasias, multiple small erosions, shiny white-red structureless areas, and leaf-like structures. This subtype is often amenable to topical or destructive therapies.

Morpheaform/Sclerosing BCC (5-10%)

Morpheaform BCC appears as a scar-like, indurated, ill-defined whitish plaque. It demonstrates an aggressive growth pattern with extensive subclinical extension that often far exceeds the clinical margins. Histologically, thin strands of basaloid cells infiltrate a dense fibrous stroma. This subtype has a high recurrence rate with standard excision, and Mohs micrographic surgery is the preferred approach.

Infiltrative BCC

Infiltrative BCC shows spiculated strands of basaloid cells infiltrating between collagen bundles. It produces less stromal response than morpheaform BCC but has more irregular borders. It is classified as a high-risk subtype requiring Mohs or wide excision.

Micronodular BCC

Micronodular BCC is composed of multiple small nodular aggregates dispersed through the dermis. It may appear clinically similar to nodular BCC, but histology reveals wider subclinical extension, resulting in a higher recurrence rate.

Basosquamous (Metatypical) BCC

This controversial entity shows mixed features of BCC and SCC. It carries higher metastatic potential than pure BCC and should be treated as a high-risk tumor with wide excision or Mohs surgery.

<image>Clinical photographs of the four main basal cell carcinoma subtypes: nodular (pearly papule with telangiectasia), superficial (erythematous patch with thread-like border), morpheaform (scar-like plaque), and pigmented (brown-black nodule)</image>

Histopathology

BCC is characterized by nests and strands of basaloid cells with large, dark nuclei and scant cytoplasm. Peripheral palisading, in which cells at the periphery of tumor nests align in an orderly fashion, is a hallmark finding. Retraction artifact (clefting), the separation of tumor nests from surrounding stroma during tissue processing, is another distinctive feature. Nodular BCC shows large, well-circumscribed tumor nests in the dermis. Superficial BCC demonstrates buds of basaloid cells attached to the undersurface of the epidermis. Morpheaform BCC reveals thin strands, often only 1 to 2 cells thick, embedded in dense sclerotic stroma, with palisading frequently absent. Mucinous stroma is common, and melanin pigment may be present in pigmented variants.

Risk Stratification

High-Risk Features (NCCN)

High-risk features include location in the H-zone of the face (central face, eyelids, eyebrows, periorbital area, nose, lips, chin, mandible, preauricular and postauricular areas, temple, and ear), genitalia, hands, or feet, or tumor size of 20 mm or greater on the trunk and extremities or 10 mm or greater on the cheeks, forehead, scalp, or neck. Histologic subtypes classified as high risk include morpheaform, infiltrative, micronodular, and basosquamous. Perineural invasion, recurrent tumors, immunosuppression, prior radiation at the site, and poorly defined clinical borders are all high-risk features.

Low-Risk Features

Low-risk tumors are small, located on the trunk or extremities, have well-defined borders, and are of nodular or superficial subtype. They lack perineural invasion and occur as primary tumors in immunocompetent patients.

<image>Anatomic diagram of the H-zone of the face highlighting high-risk areas for basal cell carcinoma recurrence requiring Mohs micrographic surgery</image>

Management

Surgical

Standard excision with 4 mm clinical margins and postoperative margin assessment is appropriate for low-risk BCC, achieving cure rates of approximately 95 percent for primary nodular BCC. Mohs micrographic surgery is the gold standard for high-risk BCC, with a 99 percent 5-year cure rate for primary BCC and 94 to 95 percent for recurrent BCC. Mohs is indicated for high-risk locations (H-zone), aggressive histologic subtypes, recurrent tumors, perineural invasion, poorly defined borders, and situations where tissue conservation is paramount, such as periocular, nasal, auricular, and lip tumors. It provides complete circumferential peripheral and deep margin assessment (CCPDMA). Curettage and electrodesiccation is appropriate for low-risk, small, well-defined nodular or superficial BCCs on the trunk and extremities. Three cycles of curettage followed by electrodesiccation achieve a cure rate of approximately 95 percent for properly selected tumors. This technique is not appropriate for morpheaform, infiltrative, or recurrent BCCs and is not recommended in hair-bearing areas where tumor may track along follicles. It provides no histologic margin assessment and heals by secondary intention.

Non-Surgical

Topical therapies are reserved for superficial BCC only. Imiquimod 5 percent cream, a TLR7 agonist, is applied five times weekly for 6 weeks with cure rates of approximately 80 to 85 percent. 5-Fluorouracil 5 percent cream, a thymidylate synthase inhibitor, is applied twice daily for 6 to 12 weeks with similar cure rates. Neither is appropriate for nodular, morpheaform, or high-risk BCCs.

Photodynamic therapy uses topical aminolevulinic acid or methyl aminolevulinate with red light. It is best suited for superficial BCC with variable results for thin nodular BCC. It provides excellent cosmesis with cure rates of 75 to 85 percent for superficial BCC but carries higher recurrence rates than surgery.

Radiation therapy is reserved for inoperable tumors, elderly or poor surgical candidates, or as adjuvant therapy for perineural invasion. The 5-year cure rate is approximately 90 percent for primary BCC. Radiation is contraindicated in Gorlin syndrome (it may induce new BCCs), in young patients (due to long-term radiation effects), and in patients with connective tissue diseases.

Hedgehog pathway inhibitors target SMO. Vismodegib is FDA-approved for locally advanced or metastatic BCC with response rates of approximately 30 to 43 percent for metastatic and approximately 60 percent for locally advanced disease. Sonidegib is a second SMO inhibitor approved for locally advanced BCC. Common side effects include muscle spasms, alopecia, dysgeusia, weight loss, and fatigue, with significant discontinuation rates. Acquired resistance through SMO mutations (D473H, D473G) develops in 15 to 20 percent of treated patients. In Gorlin syndrome, vismodegib reduces BCC burden, but side effects limit long-term use.

Cemiplimab (anti-PD-1) was FDA-approved in 2021 for locally advanced BCC previously treated with a Hedgehog inhibitor or for patients in whom Hedgehog inhibitors are not appropriate, with a response rate of approximately 31 percent and durable responses in some patients.

<image>Histopathological comparison of nodular BCC showing well-circumscribed basaloid nests with peripheral palisading and retraction artifact versus morpheaform BCC showing thin infiltrative strands in sclerotic stroma</image>

Follow-Up and Surveillance

The first 2 years carry the highest recurrence risk, and follow-up every 6 to 12 months is recommended during this period. Years 3 through 5 require annual skin examination. Lifelong surveillance is recommended given the high risk of new primary BCCs (36 to 50 percent at 5 years). Patient education should emphasize sun protection and self-examination. Gorlin syndrome patients require dermatologic evaluation every 1 to 3 months and multidisciplinary care.

Clinical Pearls

A pearly papule with arborizing telangiectasias on the nose of an elderly patient is BCC until proven otherwise -- this is the single most common presentation. Morpheaform BCC is the most dangerous subtype because of its extensive subclinical extension; clinical margins significantly underestimate tumor size. Pigmented BCC can mimic melanoma clinically, but dermoscopy readily distinguishes the two: arborizing vessels and leaf-like areas point to BCC, while a pigment network indicates a melanocytic lesion. In immunosuppressed transplant patients, the BCC-to-SCC ratio inverts -- SCCs predominate, but BCCs still occur and tend to be more aggressive. Gorlin syndrome should be suspected in any patient under 20 presenting with multiple BCCs, and genetic testing for PTCH1 mutations confirms the diagnosis.

References

• NCCN Clinical Practice Guidelines in Oncology: Basal Cell Skin Cancer, Version 2.2024
• Cameron MC, et al. Basal cell carcinoma: Epidemiology, pathophysiology, clinical and histological subtypes, and disease associations. J Am Acad Dermatol. 2019;80(2):303-317
• Migden MR, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379:341-351
• Sekulic A, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171-2179
• Verkouteren JAC, et al. Epidemiology of basal cell carcinoma: scholarly review. Br J Dermatol. 2017;177(2):359-372

Read this lecture as Markdown